Yıl: 2015 Cilt: 30 Sayı: 1 Sayfa Aralığı: 28 - 33 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Clinical features, treatment and monitoring in patients with polymyalgia rheumatica

Öz:
Amaç: Bu çalışmada polimiyalji romatikalı Türk hastaların klinik semptomları ve laboratuvar bulguları değerlendirildi. Hastalar ve yöntemler: Polimiyalji romatikalı 41 hastanın (9 erkek, 32 kadın; ort. yaş 65.5±7.6 yıl; dağılım 60-80 yıl) klinik verileri retrospektif olarak değerlendirildi. Hastaların klinik semptomları, laboratuvar bulguları, tedavileri ve tedaviye yanıtları incelendi. Bulgular: En yaygın semptomlar iki taraflı omuz ağrısı (%59.9) ve sabah tutukluğu (%48.78) idi. Tanı sırasında ortalama eritrosit sedimentasyon hızı 66.8±22.5 mm/s iken, ortalama C-reaktif protein değeri 48.7±25.8 mg/dL idi. Kortikosteroid tedavisinin üçüncü haftasında 33 hastada (%80.5) tedaviye iyi yanıt saptandı. Tedaviye iyi yanıt veren hastaların yaş ortalaması (67.2±6.7) tedaviye yetersiz yanıt veren veya hiç yanıt vermeyen hastaların yaş ortalamasından (58.5±7.8) yüksekti (p=0.009). Sonuç: Hastaların klinik özellikleri, laboratuvar bulguları, başlangıç steroid dozları ve kortikosteroid tedavisine yanıtları literatür ile uyumlu idi. Ancak sabah tutukluğu oranı yüksek, periferik artrit nadir idi. Polimiyalji romatikalı hastalarda dev hücreli arterit saptanmadı. Erken steroid tedavisine iyi yanıt daha yaşlı hastalarda gözlemlendi. Nüks oranı düşük idi. Tedaviye yanıtı, remisyonu ve nüksü etkileyen faktörleri değerlendirmek için ileri çalışmalar gereklidir.
Anahtar Kelime:

Konular: Romatoloji

Polimiyalji romatikalı hastalarda klinik özellikler, tedavi ve takip

Öz:
Objectives: This study aims to evaluate the clinical symptoms and laboratory findings of Turkish patients with polymyalgia rheumatica. Patients and methods: Clinical data of 41 patients (9 males, 32 females; mean age 65.5±7.6 years; range 60 to 80 years) with polymyalgia rheumatica were retrospectively evaluated. Patients clinical symptoms, laboratory findings, therapies and therapeutic responses were analyzed. Results: The most common symptoms were bilateral shoulder pain (59.9%) and morning stiffness (48.78%). Mean erythrocyte sedimentation rate at diagnosis was 66.8±22.5 mm/h, while mean C-reactive protein value was 48.7±25.8 mg/dL. In the third week of corticosteroid treatment, good response to treatment was detected in 33 patients (80.5%). Mean age of patients who gave good response to treatment (67.2±6.7) was higher than mean age of patients who gave poor or no response to treatment (58.5±7.8) (p=0.009). Conclusion: Patients clinical features, laboratory findings, initial steroid doses, and responses to corticosteroid therapy were consistent with the literature. However, the rate of morning stiffness was high and peripheral arthritis was rare. Giant cell arteritis was not detected in patients with polymyalgia rheumatica. Good response to early steroid treatment was observed in older patients. Rate of relapse was low. Further studies are required to evaluate factors affecting response to treatment, remission, and relapse.
Anahtar Kelime:

Konular: Romatoloji
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Michet CJ, Matteson EL. Polymyalgia rheumatica. BMJ 2008;336:765-9.
  • Bruce W. Senile Rheumatic Gout. Br Med J 1888;2:811-3.
  • Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979;38:434-9.
  • Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982;97:672-80.
  • Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984;13:322-8.
  • Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012;64:943-54.
  • Doran MF, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 2002;29:1694-7.
  • Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
  • Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez- Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61:1454-61.
  • Helliwell T, Hider SL, Mallen CD. Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice. Br J Gen Pract 2013;63:361-6.
  • Hernández-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch X. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 2009;169:1839-50.
  • Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234-45.
  • Lee JH, Choi ST, Kim JS, Yoon BY, Kwok SK, Kim HS, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int 2013;33:1475-80.
  • Pipitone N, Salvarani C. Update on polymyalgia rheumatica. Eur J Intern Med 2013;24:583-9.
  • Salvarani C, Cantini F, Macchioni P, Olivieri I, Niccoli L, Padula A, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 1998;41:1221-6.
  • Ceccato F, Roverano SG, Papasidero S, Barrionuevo A, Rillo OL, Paira SO. Peripheral musculoskeletal manifestations in polymyalgia rheumatica. J Clin Rheumatol 2006;12:167-71.
  • Mazzantini M, Torre C, Miccoli M, Baggiani A, Talarico R, Bombardieri S, et al. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol 2012;39:552-7.
  • Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 2010;49:186-90.
  • Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet 2013;381:63-72.
  • van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996;55:218-23.
  • Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, doubleblind, placebo-controlled trial. Ann Intern Med 2004;141:493-500.
  • Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007;146:631-9.
  • De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;45:136-8.
  • Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int 2013;2013:120638.
  • Al Rashidi A, Hegazi MO, Mohammad SA, Varghese A. Effective control of polymyalgia rheumatica with tocilizumab. J Clin Rheumatol 2013;19:400-1.
  • Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R, et al. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum 2013;43:113-8.
  • Kim HA, Lee J, Ha YJ, Kim SH, Lee CH, Choi HJ, et al. Induction of remission is difficult due to frequent relapse during tapering steroids in Korean patients with polymyalgia rheumatica. J Korean Med Sci 2012;27:22-6.
APA Yurdakul F, Bodur H, SİVAS F, Başkan B, Eser F, yılmaz o (2015). Clinical features, treatment and monitoring in patients with polymyalgia rheumatica. , 28 - 33.
Chicago Yurdakul Fatma,Bodur Hatice,SİVAS Filiz,Başkan Bedriye,Eser Filiz,yılmaz onur Clinical features, treatment and monitoring in patients with polymyalgia rheumatica. (2015): 28 - 33.
MLA Yurdakul Fatma,Bodur Hatice,SİVAS Filiz,Başkan Bedriye,Eser Filiz,yılmaz onur Clinical features, treatment and monitoring in patients with polymyalgia rheumatica. , 2015, ss.28 - 33.
AMA Yurdakul F,Bodur H,SİVAS F,Başkan B,Eser F,yılmaz o Clinical features, treatment and monitoring in patients with polymyalgia rheumatica. . 2015; 28 - 33.
Vancouver Yurdakul F,Bodur H,SİVAS F,Başkan B,Eser F,yılmaz o Clinical features, treatment and monitoring in patients with polymyalgia rheumatica. . 2015; 28 - 33.
IEEE Yurdakul F,Bodur H,SİVAS F,Başkan B,Eser F,yılmaz o "Clinical features, treatment and monitoring in patients with polymyalgia rheumatica." , ss.28 - 33, 2015.
ISNAD Yurdakul, Fatma vd. "Clinical features, treatment and monitoring in patients with polymyalgia rheumatica". (2015), 28-33.
APA Yurdakul F, Bodur H, SİVAS F, Başkan B, Eser F, yılmaz o (2015). Clinical features, treatment and monitoring in patients with polymyalgia rheumatica. Archives of Rheumatology, 30(1), 28 - 33.
Chicago Yurdakul Fatma,Bodur Hatice,SİVAS Filiz,Başkan Bedriye,Eser Filiz,yılmaz onur Clinical features, treatment and monitoring in patients with polymyalgia rheumatica. Archives of Rheumatology 30, no.1 (2015): 28 - 33.
MLA Yurdakul Fatma,Bodur Hatice,SİVAS Filiz,Başkan Bedriye,Eser Filiz,yılmaz onur Clinical features, treatment and monitoring in patients with polymyalgia rheumatica. Archives of Rheumatology, vol.30, no.1, 2015, ss.28 - 33.
AMA Yurdakul F,Bodur H,SİVAS F,Başkan B,Eser F,yılmaz o Clinical features, treatment and monitoring in patients with polymyalgia rheumatica. Archives of Rheumatology. 2015; 30(1): 28 - 33.
Vancouver Yurdakul F,Bodur H,SİVAS F,Başkan B,Eser F,yılmaz o Clinical features, treatment and monitoring in patients with polymyalgia rheumatica. Archives of Rheumatology. 2015; 30(1): 28 - 33.
IEEE Yurdakul F,Bodur H,SİVAS F,Başkan B,Eser F,yılmaz o "Clinical features, treatment and monitoring in patients with polymyalgia rheumatica." Archives of Rheumatology, 30, ss.28 - 33, 2015.
ISNAD Yurdakul, Fatma vd. "Clinical features, treatment and monitoring in patients with polymyalgia rheumatica". Archives of Rheumatology 30/1 (2015), 28-33.